LIMS Labware CSV GAP Assessment

A prominent German pharmaceutical company, specializing in advanced formulations and biotechnology, implemented a Laboratory Information Management System (LIMS) using Labware to optimize laboratory workflows and data management. The system was validated internally, but the company sought an expert review to ensure compliance with regulatory requirements, including FDA 21 CFR Part 11, EU Annex 11, and GAMP5 guidelines.

Zamann Pharma Support was engaged to perform a thorough GAP Assessment of all validation documents generated during the LIMS Computerized System Validation (CSV) process. The objective was to identify deficiencies, ensure adherence to regulatory standards, and propose corrective and preventive actions (CAPAs) to address any gaps.

Challenges Faced

Inconsistent structure and incomplete information in validation documents.
Lack of alignment with GAMP5 principles, particularly regarding risk-based validation and system classification.
GAPs in critical documents, such as User Requirements Specifications (URS), Validation Plans, and Validation Reports.
Limited traceability between test scripts and system requirements, raising concerns about the integrity of the validation process.
Risk of non-compliance during upcoming regulatory inspections.

Zamann Pharma Support’s Approach

Document Review and Analysis: Zamann Pharma Support initiated the GAP Assessment by systematically reviewing all CSV documents, including:
- Validation Plan: Evaluated the scope, objectives, and approach defined for the validation process.
- User Requirements Specification (URS): Assessed whether the documented requirements were complete, testable, and aligned with business and regulatory needs.
- Risk Assessment: Verified that a proper risk management framework was applied, ensuring critical aspects were addressed adequately.
- Traceability Matrix: Checked for gaps in linking system requirements to corresponding validation activities.
- Test Scripts: Analyzed the content and execution of Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) tests for completeness and accuracy.
- Validation Summary Report: Ensured that the final report provided a comprehensive evaluation of the validation outcomes and compliance.

Regulatory and GAMP5 Alignment: The team compared the documentation against the requirements of:
- FDA 21 CFR Part 11 for electronic records and signatures.
- EU Annex 11 for computerized system validation in pharmaceutical environments.
- GAMP5 guidelines, focusing on a risk-based approach and lifecycle management principles.

GAP Identification: Key gaps identified during the assessment included:
- Missing or incomplete documentation of system functionalities in the URS.
- Insufficient evidence of risk-based decision-making in validation activities.
- Weak traceability between requirements, test cases, and results.
- Ambiguities in defining roles and responsibilities for validation tasks.
- Lack of post-validation periodic review plans for the LIMS system.

Structured Findings: Delivered a detailed report with observations categorized into:
- Critical GAPs: Direct non-conformances with FDA regulations or GAMP5 principles.
- Major GAPs: Areas that could lead to regulatory observations if not addressed.
- Minor GAPs: Opportunities to enhance documentation quality and robustness.

CAPA Development: Zamann Pharma Support proposed a structured CAPA plan to address the identified deficiencies, including:
- Revising the URS to clearly document all system functionalities and compliance requirements.
- Incorporating a robust risk assessment framework aligned with GAMP5 principles.
- Enhancing traceability by updating the Traceability Matrix to link all requirements, tests, and results.
- Conducting training sessions to improve the understanding of validation principles among staff.
- Establishing a process for periodic review and revalidation of the LIMS system.

Client Engagement and Knowledge Transfer:
- Regular meetings with the client’s QA, IT, and laboratory teams ensured alignment on findings and proposed solutions.
- Workshops were conducted to explain the identified gaps, regulatory expectations, and best practices for future validations.

Results Achieved

Improved Compliance: The revised validation documentation fully aligned with FDA, EU, and GAMP5 requirements, reducing regulatory risks.
Enhanced Traceability: The updated Traceability Matrix ensured end-to-end traceability between requirements and validation activities.
Strengthened Risk Management: The risk assessment process was enhanced to prioritize critical areas and streamline validation efforts.
Knowledge Empowerment: Staff gained a better understanding of CSV principles, enabling them to manage future validations independently.
Regulatory Success: During a subsequent regulatory inspection, the LIMS validation documentation was reviewed without findings, confirming the robustness of the revised approach.

Client Testimonial

“Zamann Pharma Support’s expertise was invaluable in identifying and resolving gaps in our LIMS validation documentation. Their structured approach, clear communication, and practical recommendations have elevated our compliance standards. We are now confident in the integrity of our systems and our preparedness for future audits.”

Contact Us

Need help? Don't hesitate to get in touch

First Name*

Last Name*

Email*

Phone number*

Role*

Department*

Country

Industry

Question submitted

Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.

Yes, I agree to receive personalized newsletters with market insights, invitations for exclusive events and educational webinars from the Zamann Pharma Support GmbH.

I consent to the privacy policy and understand that my personal data will be stored and processed*

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com